Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase made the announcement because its relevant.
View:
Post by floatinketucky on Jan 20, 2022 5:44pm

Theralase made the announcement because its relevant.

Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce that Theralase researchers; specifically: University Health Network (“UHN”) and the University of Toronto (“UT”) have received an Ontario Research Fund – Research Excellence (“ORF-RE”) grant with a primary mandate of advancing personalized Anti-Cancer Photo Dynamic Therapy (“PDT”) for each individual cancer patient to safely and effectively destroy their particular cancer, while maintaining the highest possible quality of life for them.


Do you think another BLADDER PDT treatment is out there getting the funding? If another treatment got the funding why would Theralase be pleased to annouce it? Would Theralse be please to annouce that a competitor recieved the government funds???  Is that what you think??   

Simply put... If it had nothing to to with Theralse is would be 
unconscionable for them to PR that data. 

They were pleased to annouce it because it is relavent to the company. 
Comment by floatinketucky on Jan 20, 2022 5:47pm
hey Maybe Merc got the funding and Theralse wanted to congradulate em??   LMFAO.. DONT FREAKIN THINK SO Hope ya like chasing higher prices. 
Comment by CAinPlap on Jan 21, 2022 10:02am
My point was that the funding money did not end up in Theralase's bank account and is not under our control. Yes it will benefit TLT indirectly. I own enough that I will not feel the need to chase. Thanks for your efforts in promoting our investment!
Comment by floatinketucky on Jan 21, 2022 10:08am
Good point. I think there was never confusion that Theralase would recieve money in the company account.  The op ex will get the windfall. I read last night the the usual dispersment is 1 million dollars.  Have a great day TLTFF Long
Comment by floatinketucky on Feb 08, 2022 8:20am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250